Financial News
Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year
June 21, 2024 at 15:45 PM EDT
Some patients with obstructive sleep apnea and obesity who took the highest dose of Zepbound achieved "disease resolution," in the two trials.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
